This effect is thought to be mediated through GLP-1 receptors in the cardiovascular system and is generally not clinically significant, though patients with certain arrhythmias or those sensitive to heart rate changes should be monitored
FDA published meeting minutes from its Biosimilar User Fee Act (BsUFA) reauthorization meeting on 12 May with industry representatives, including the Association for Accessible Medicines, the Biotechnology Innovation Organization (BIO), the Biosimilars Forum, and PhRMA
As an NNMT inhibitor, it is associated with reduced white adipose tissue, improved NAD+ availability, and support for insulin sensitivity
It has this action by acting as a cofactor in different pathways of the body
Healthcare providers should be aware of these potential side effects and monitor patients closely during treatment